Targeting immunoliposomes to EGFR-positive glioblastoma

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor often associated with epidermal growth factor receptor (EGFR) amplification.
• Targeted drug delivery systems, such as immunoliposomes, are being investigated to improve treatment efficacy and reduce systemic toxicity.
• EGFR-targeted immunoliposomes offer a potential strategy for delivering therapeutic agents directly to GBM cells.

Purpose of the Study:

• To assess the tolerability and effectiveness of anti-EGFR immunoliposomes loaded with doxorubicin (anti-EGFR ILs-dox) in patients with relapsed glioblastoma.
• To evaluate the capacity of EGFR-targeted immunoliposomes to deliver cargo to brain tumor tissue.
• To determine the pharmacokinetic profile of anti-EGFR ILs-dox in plasma, cerebrospinal fluid (CSF), and tumor tissue.

Main Methods:

• A phase I pharmacokinetic trial was conducted involving patients with EGFR-amplified, relapsed glioblastoma.
• Patients received up to four cycles of anti-EGFR ILs-dox.
• Doxorubicin concentrations were measured in plasma, CSF, and tumor tissue 24 hours post-administration. Safety and efficacy parameters were also assessed.

Main Results:

• Anti-EGFR ILs-dox did not cross the intact blood-brain barrier (BBB), with negligible doxorubicin levels detected in CSF.
• Significant doxorubicin concentrations were found in glioblastoma tissue, indicating successful liposome delivery into the tumor.
• No new safety issues were observed. Median progression-free survival was 1.5 months and median overall survival was 8 months.

Conclusions:

• EGFR-targeted immunoliposomes can be effectively targeted to EGFR-amplified glioblastoma.
• Cargo, such as doxorubicin, can be delivered to brain tumor tissue via these immunoliposomes, despite not crossing the intact BBB.
• Neoadjuvant administration may positively impact patient outcomes, as suggested by one patient's prolonged remission.